Pharmaceutical News

RSS

Study examines effects of intravenous glutamine on hind limb ischemia reperfusion injury

A single dose of intravenous glutamine (GLN) administered immediately after a non-lethal lower limb ischemia reduces the reperfusion inflammatory reaction locally and systemically according to a new study.

10 Jun 2015

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of the investigational therapy Praluent (alirocumab) Injection.

9 Jun 2015

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Ampio Pharmaceuticals, Inc. today announced three peer-review publications that report the multifaceted and synergistic effects of Ampion in the treatment of osteoarthritis in the knee.

9 Jun 2015

Lycera forms exclusive global collaboration with Celgene

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the formation of an exclusive global collaboration with Celgene Corporation to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases.

9 Jun 2015

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope, the drug discovery and development company focused on disease-modifying treatments that reinstate immune tolerance, announced today that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the US Food and Drug Administration for the prevention or treatment of inhibitors in haemophilia A patients with inhibitors or at the risk of producing inhibitors.

9 Jun 2015

Nature's Bounty introduces Women's Multivitamin Gummies

Nature's Bounty, one of the most trusted names in vitamins, supplements and nutrition, is excited to introduce its Women's Multivitamin Gummies, the newest addition to the Optimal Solutions health, beauty and wellness line. This supplement helps provide women with the nutrients needed to support a healthy, strong and beautiful body.

9 Jun 2015

HOPA Oncology Pharmacy Practice Management Program to be held on Sept. 18-19, 2015 in Illinois

The Hematology/Oncology Pharmacy Association (HOPA) will present the HOPA Oncology Pharmacy Practice Management Program at the Hilton Rosemont/Chicago O'Hare on September 18-19, 2015, in Rosemont, IL.

9 Jun 2015

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.

9 Jun 2015

People now have powerful new option for relieving dry mouth symptoms

People who suffer from dry mouth, or xerostomia, now have a powerful new option for relieving their symptoms. Building on the success of its antioxidant oral care product line, Dallas-based PerioSciences LLC is launching Dry Mouth AO ProGel and a new MILD formula of its Hydrating AO ProRinse. The new products, along with the established Hydrating AO ProRinse and AO ProToothpaste, provide a complete Hydrating Oral Care System.

8 Jun 2015

Global RA treatment market expected to increase just over $19 billion by 2020

Analysis from business intelligence provider GBI Research - Rheumatoid Arthritis Market to 2020 - says that the global Rheumatoid Arthritis (RA) treatment market is expected to increase in value, from $14.3 billion in 2013 to just over $19 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 4.1%.

8 Jun 2015

New study gives insight into the mental health of teens, children with Down syndrome

A new study gives insight into the mental health of children and teens with Down syndrome and the behavioral medications that medical caregivers sometimes prescribe for them.

8 Jun 2015

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.

8 Jun 2015

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

Type 1 diabetes, which usually appears in children and adolescents, affects over 30 million people worldwide. Resulting from an auto-immune reaction that destroys the pancreatic beta cells that produce insulin, the disease leads to pathologically high levels of sugar in the blood and urine, resulting in high rates of morbidity and mortality. The current treatment for Type 1 diabetes is lifetime administration of insulin by injection.

8 Jun 2015

St. Michael's Hospital researchers find novel method to combat flu virus

The flu kills hundreds of thousands of people around the world every year, yet there is essentially only one class of drugs to fight the ever-changing virus. Cases of flu resistant to this class of drugs have already been reported and researchers worry a completely new strain of flu could evolve, leading to a pandemic like the one in 1918 that killed approximately 50 million people.

8 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

The All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. The recommendation is specifically for patients with advanced liver disease, for whom treatment options can be limited.

5 Jun 2015

Withholding ARBs for longer than two days after surgery significantly increases risk of postoperative death

Withholding angiotensin receptor blockers (ARBs) for longer than two days after surgery is associated with a significantly increased risk of postoperative death, according to a study of more than 30,000 patients in the VA health care system by researchers at UC San Francisco and the San Francisco VA Medical Center.

5 Jun 2015

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration's tentative approval last week of lopinavir/ritonavir (LPV/r) oral pellets developed by the Indian generic company Cipla.

5 Jun 2015

First phase of Amway's new $81 million nutrition manufacturing facility opens in Ada, Michigan

Amway today announced the opening of the first phase of its new $81 million USD nutrition manufacturing facility in Ada, Michigan, USA, near its world headquarters. The 317,000-square-foot facility will house select manufacturing operations for the company's Nutrilite brand of vitamins, minerals and dietary supplements, sold exclusively by Amway Business Owners.

4 Jun 2015

Updated SOGC guidelines include FIBRISTAL as only approved medical treatment for uterine fibroids

The Society for Obstetrics and Gynecology of Canada has issued updated guidelines for the management of uterine fibroids (uterine leiomyomas), which now include the first and only approved medical treatment for uterine fibroids: FIBRISTAL (ulipristal acetate).

4 Jun 2015

Pharmaceutical News

Study examines effects of intravenous glutamine on hind limb ischemia reperfusion injury

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Ampio reports effects of Ampion in treating chronic pain caused by osteoarthritis of the knee

Lycera forms exclusive global collaboration with Celgene

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Nature's Bounty introduces Women's Multivitamin Gummies

HOPA Oncology Pharmacy Practice Management Program to be held on Sept. 18-19, 2015 in Illinois

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

People now have powerful new option for relieving dry mouth symptoms

Global RA treatment market expected to increase just over $19 billion by 2020

New study gives insight into the mental health of teens, children with Down syndrome

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

BioLineRx's BL-9020 antibody holds promise in treating Type 1 diabetes

St. Michael's Hospital researchers find novel method to combat flu virus

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

Withholding ARBs for longer than two days after surgery significantly increases risk of postoperative death

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

First phase of Amway's new $81 million nutrition manufacturing facility opens in Ada, Michigan

Updated SOGC guidelines include FIBRISTAL as only approved medical treatment for uterine fibroids

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News